Brokerages Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Price Target at $28.14

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has earned an average rating of “Hold” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $28.1429.

Several brokerages have issued reports on KMTS. JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective on the stock. Oppenheimer started coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, September 2nd. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 31st.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $24.07 on Monday. The stock has a market cap of $1.41 billion, a P/E ratio of -9.95 and a beta of 0.62. Kestra Medical Technologies has a twelve month low of $17.34 and a twelve month high of $30.00. The stock has a 50 day moving average of $25.49 and a two-hundred day moving average of $22.73. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. On average, research analysts forecast that Kestra Medical Technologies will post -2.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Traci Umberger sold 8,752 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $22.60, for a total transaction of $197,795.20. Following the completion of the sale, the insider owned 206,995 shares in the company, valued at $4,678,087. This represents a 4.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Timothy Moran sold 8,759 shares of Kestra Medical Technologies stock in a transaction on Friday, July 31st. The shares were sold at an average price of $22.61, for a total transaction of $198,040.99. Following the completion of the transaction, the insider owned 68,725 shares in the company, valued at approximately $1,553,872.25. This trade represents a 11.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 238,164 shares of company stock valued at $5,700,952. 5.30% of the stock is owned by company insiders.

Institutional Trading of Kestra Medical Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Grand Managers LLC purchased a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $2,652,000. Eventide Asset Management LLC lifted its holdings in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares during the period. Sei Investments Co. boosted its stake in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares in the last quarter. UBS Group AG boosted its stake in shares of Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after buying an additional 69,908 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies during the fourth quarter worth $9,282,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.